REFERENCES
- Brown M., Glick H.A., Harrell F., Herndon J., McCabe M., Moinpour C., Schulman K.A., Smith T., Weeks J., Seils D.M. Integrating Economic Analysis into Cancer Clinical Trials: The National Cancer Institute—American Society of Clinical Oncology. Econ. Workbook J. Natl Cancer Inst. Monogr. 1998; 24: 1–28
- Kurz X., Torfs K., Bussels J., Annemans L. Introduction aux Évaluations Économiques en Matière de Soins de Santé. Astra Pharm. 2000
- Levi F., Zidani R., Misset J.L. Randomised Multicentre Trial of Chronotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid in Metastatic Colorectal Cancer. Lancet 1997; 350: 681–686
- Lévi F., Zidani R., Vannetzel J.M., Perpont B., Focan C., Faggiulo R., Chollet P., Garufi C., Itzhaki M., Dogliotti L., Iacobelli S., Adam R., Kunstlinger F., Gastiaburu J., Bismuth H., Jasmin C., Misset J.L. Chronomodulated Versus Fixed Infusion Rate Delivery of Ambulatory Chemotherapy with Oxaliplatin, 5-Fluorouracil and Folinic Acid in Patients with Colorectal Cancer Metastases: A Randomized Multiinstitutional Trial. J. Natl Cancer Inst. 1994; 86: 1608–1617
- Levi F., Zidani R., Llory J., Dogliotti L., Perpoint B., Iacobelli S., Chollet P., Focan C., Garufi C., Le Rol A., Giachetti S., Misset J. Final Efficacy Update at 7 Years of Flat vs Chronomodulated Infusion of Oxaliplatin, 5-Fluoruracil and Leucovorin as First Line Treatment of Metastatic Colorectal Cancer. Proc. ASCO 2000; 19(936)242a
- Roy T., Neymark N., Wils J., Koehne C.H., Schmoll H.J. Chemotherapy as Primary Treatment in Advanced Colorectal Cancer: Economic Evaluation of Three Different 5-FU Schedules. Eur. J. Cancer 2000; 36(Suppl. 3)S6(OP22)
- Lüthi F., Leyvraz S., Rollier P., Bauer J., Fucina N., Divorne N., Wasserfallen J.B. Cost Comparison Between Hospital and Home Chemotherapy: A Pilot Study. Eur. J. Cancer 2000; 36(Suppl. 3)S21(PP43)
- Remonnay R., Devaux T., Späth H., Chauvin F., Carrere M.O. Comparison of Marginal and Average Costs of Chemotherapy in Hospital at Home Versus Standard Hospital Care. Eur. J. Cancer 2000; 36(Suppl. 3)S5(OP20)